G2GBIO (A456160) Stock Overview
A clinical-stage biotech company, provides pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A456160 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
G2GBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩46,700.00 |
| 52 Week High | ₩124,000.00 |
| 52 Week Low | ₩27,566.67 |
| Beta | 0 |
| 1 Month Change | -35.32% |
| 3 Month Change | -58.85% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 49.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| A456160 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -13.0% | -7.6% | -7.9% |
| 1Y | n/a | 7.3% | 164.6% |
Return vs Industry: Insufficient data to determine how A456160 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A456160 performed against the KR Market.
Price Volatility
| A456160 volatility | |
|---|---|
| A456160 Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in KR Market | 15.9% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A456160's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A456160's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Hee-yong Lee | www.g2gbio.com |
G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.
G2GBIO Inc. Fundamentals Summary
| A456160 fundamental statistics | |
|---|---|
| Market cap | ₩772.67b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
Is A456160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A456160 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A456160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 23:25 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
G2GBIO Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.